Livforsakringsbolaget Skandia’s Sarepta Therapeutics SRPT Stock Holding History

Livforsakringsbolaget Skandia’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-700	Closed	-$52K	–	678
2021 Q1	$52K	Hold	700	–	–	﹤0.01%	651
2020 Q4	$119K	Hold	700	–	–	0.01%	557
2020 Q3	$98K	Hold	700	–	–	0.01%	550
2020 Q2	$112K	Hold	700	–	–	0.01%	504
2020 Q1	$68K	Hold	700	–	–	0.01%	555
2019 Q4	$90K	Sell	700 -500	-42%	-$50.5K	0.01%	534
2019 Q3	$90K	Buy	+1,200	New	+$142K	0.01%	538

Other funds holding SRPT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Livforsakringsbolaget Skandia's SRPT Position: Q2 2021 in Review

Livforsakringsbolaget Skandia sold out of Sarepta Therapeutics (SRPT) in Q2 2021, closing a stake of 700 shares — an estimated $52K sold.

Livforsakringsbolaget Skandia first reported a position in SRPT in Q3 2019 and held it in 7 quarters. The position peaked at $119K in Q4 2020. 331 funds tracked by Wall St. Rank hold SRPT as of Q2 2021.

Livforsakringsbolaget Skandia reported no remaining Sarepta Therapeutics position as of Q2 2021 after selling out during the quarter.
Livforsakringsbolaget Skandia sold 700 Sarepta Therapeutics shares in Q2 2021, an estimated $52K.
Livforsakringsbolaget Skandia first reported a position in Sarepta Therapeutics in Q3 2019 and held it in 7 quarters.
Livforsakringsbolaget Skandia's Sarepta Therapeutics position peaked at $119K in Q4 2020.
331 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2021.

Based on Livforsakringsbolaget Skandia's 13F filing for Q2 2021, filed 13 Jul 2021.